licensing « Science and Enterprise

In one of its first actions, the Biden administration rejoined the United States in the World Health Organization,… https://t.co/gpHTTr70DP
about 12 hours ago
New post on Science and Enterprise: U.S. Rejoins WHO, Participates in Int’l Vaccine Project https://t.co/bBUZr5UzSg #Science #Business
about 12 hours ago
A clinical trial shows long-term care residents and staff receiving a synthetic antibody treatment have a lower ris… https://t.co/EPYrP8wElE
about 16 hours ago
New post on Science and Enterprise: Antibodies Prevent Covid-19 Symptoms in Long-Term Care https://t.co/sePqojZMVd #Science #Business
about 16 hours ago
Another way to connect 100 million people end-to-end with Covid-19 vaccines. https://t.co/wIWk0XNDhv
about 1 day ago

Crispr Heart Disease Biotech Raises $94M in New Funds

By Alan, on January 19th, 2021%

A company applying Crispr gene-editing technology to treat inherited heart disease is raising $94 million in its second venture funding round. . . . → Read More: Crispr Heart Disease Biotech Raises $94M in New Funds

Universities Form Joint Engineering Patent Pool

By Alan, on January 15th, 2021%

A group of 15 American universities are putting part of their engineering patents into a common licensing pool for commercial development. . . . → Read More: Universities Form Joint Engineering Patent Pool

Biotech Licenses mRNA Technology for Aging

By Alan, on January 13th, 2021%

A biotechnology enterprise is licensing research from Stanford University on messenger RNA to produce proteins that rejuvenate cells damaged by aging. . . . → Read More: Biotech Licenses mRNA Technology for Aging

Drug Maker Gains Access to Hidden Protein Immunotherapies

By Alan, on January 12th, 2021%

Global drug maker Boehringer Ingelheim is gaining access to an immunotherapy technology that targets usually hidden proteins to attack cancer cells. . . . → Read More: Drug Maker Gains Access to Hidden Protein Immunotherapies

Drug Price Disruptor Biotech Raises $500M in New Funds

By Alan, on January 11th, 2021%

A start-up biotechnology company that aims to bring drugs to market at lower cost is raising $500 million in its second venture funding round. . . . → Read More: Drug Price Disruptor Biotech Raises $500M in New Funds

Digital Therapeutics Designed for Cancer/Covid-19 Stress

By Alan, on January 8th, 2021%

A digital health company is partnering with cancer advocacy organizations to provide electronic therapies to help patients deal with stresses from Covid-19. . . . → Read More: Digital Therapeutics Designed for Cancer/Covid-19 Stress

AbbVie Acquires Coronavirus Antibody Therapy

By Alan, on December 15th, 2020%

Drug maker AbbVie is licensing a synthetic antibody to treat Covid-19 and SARS coronaviruses that the company began funding in June. . . . → Read More: AbbVie Acquires Coronavirus Antibody Therapy

Biotech Licenses Precision Cancer Biologic to Genentech

By Alan, on December 14th, 2020%

A biotechnology company discovering synthetic proteins that target cancer-causing genetic mutations is licensing its lead product to biologics maker Genentech. . . . → Read More: Biotech Licenses Precision Cancer Biologic to Genentech

Trial Shows Stem Cell Therapy Slows M.S. Progression

By Alan, on December 8th, 2020%

Results of a clinical trial show a treatment for multiple sclerosis from patients’ stem cells slows progression of the disease and improves walking ability. . . . → Read More: Trial Shows Stem Cell Therapy Slows M.S. Progression

Bayer Gains Lung Cancer Therapy in $670M Deal

By Alan, on December 7th, 2020%

Global drug maker Bayer AG is licensing an engineered T-cell therapy to treat mesothelioma and other solid tumor cancers from biotech Atara Biotherapeutics. . . . → Read More: Bayer Gains Lung Cancer Therapy in $670M Deal

Science & Enterprise subscription

Specials

Follow us on Twitter

Guest Posts

Please share Science & Enterprise